Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Long Term Debt To Equity Ratio?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Long Term Debt To Equity Ratio is 
0.21 (1Y -4.26% )

ALXN Stock Price & Long Term Debt To Equity Ratio

Long Term Debt To Equity Ratio for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Long Term Debt To Equity Ratio

chevron_right 2021 0.21 +1.0x
( +2.5% / year avg)
chevron_left 1995 0.11
vertical_align_top Peak 2.87 +391x
vertical_align_bottom Bottom 0.01
arrow_drop_up # Up Years 14 14 of 27
years up.
arrow_drop_down # Down Years 13
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +45.0x faster than it's long term debt to equity ratio over the same period.
  • If ALXN grows it's stock at the same rate as it's long term debt to equity ratio (+2.5%/year) , it's stock price will grow +128% and hit $139.17 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 14 years (0%) it's long term debt to equity ratio were also up.
5-Year Change 🚀
+138%$6.4BNet Revenue (Sales)
+181%$608.8MCost of Revenue (Sales)
+135%$5.8BGross Profit Margin
-1.58%3.62Gross Profit Margin Ratio
+78.1%$1.2BResearch and Development (R&D)
+109%$1.8BSelling, General, and Administrative (SG&A)
+91.1%$3.2BTotal Operating Expenses
+101%$3.8BCost & Expenses
+38.7%$110.8MInterest Expense/Income, Net
+51.0%$300.4MDepreciation & Amortization (D&A)
+191%$2.9BEBITDA
+22.2%1.81EBITDA Margin
+227%$2.6BOperating Income
+37.0%1.63Operating Margin
-25.4%-$114.8MTotal Other Income/Expenses
+323%$2.4BPretax Income (Earnings)
+77.5%1.48Pretax Income (Earnings) Margin
-83.0%$219.2MProvision For Income Taxes
-391.6%$2.1BNet Income (Earnings)
-222.1%1.35Net Profit Margin
-401.9%9.78Earnings Per Share (EPS)
-401.9%9.78Earnings Per Share (EPS) Diluted
-3.15%$876.4MShares Outstanding
-3.15%$876.4MShares Outstanding (Diluted)
+154%$11.9BCash and Cash Equivalents
-88.2%$139.6MShort Term Investments
+105%$12.0BCash And Short-Term Investments
+227%$3.1BInventory
+135%$23.3BTotal Current Assets
+136%$5.8BPP&E
+1.69%$20.4BGoodwill
-37.3%$12.0BIntangible Assets
-17.4%$32.4BGoodwill and Intangible Assets
+37.6%$72.4BTotal Assets
+152%$474.4MAccounts Payables
-18.6%$569.6MShort-term Debt
+6,334%$1.1BOther Current Liabilities
+111%$6.5BTotal Current Liabilities
-27.2%$9.7BLong-term Debt
+291%$6.5BDeferred Tax Liabilities Non-Current
+147%$2.4BOther Non-Current Liabilities
+16.8%$19.3BTotal Non-Current Liabilities
+31.7%$25.8BTotal Liabilities
+370%$21.0BRetained Earnings
-331.5%-$500.0MAccumulated Other Comprehensive Income Loss
+41.2%$46.6BTotal Shareholders Equity
+37.6%$72.4BTotal Liabilities & Stockholders Equity
-26.8%$10.2BTotal Debt
-117.2%-$1.6BNet Debt
-128.0%-$436.8MDeferred Income Tax
+67.5%$342.0MStock-Based Compensation (SBC)
-1,029.8%$1.9BChange in Working Capital
+144%$176.4MAccounts Receivables
+145%$16.8BOther Working Capital
-154.3%-$67.2MOther Non-Cash Items
+276%$3.4BNet Cash Provided by Operating Activities
+1.9%-$310.0MInvestments in PP&E
-97.1%-$22.4MPurchase of Investments
-96.5%$10.0MSales/Maturities of Investments
-58.7%-$322.4MNet Cash used for Investing Activities
-16.7%-$306.0MCommon Stock Repurchased
-98.9%-$4.8MOther Financing Activities
-60.1%-$295.2MNet Cash Used Provided by Financing Activities
-1,272.3%$80.0MEffect of Exchange Rate Changes on Cash
-544.5%$2.8BNet Change in Cash
+160%$12.1BCash at End of Period
+76.1%$9.3BCash at Beginning of Period
+276%$3.4BOperating Cash Flow
+1.9%-$310.0MCapital Expenditure (capex)
+418%$3.1BFree Cash Flow
  • ALXN Historical Long Term Debt To Equity Ratio Table

    Year Long Term Debt To Equity Ratio YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 0.21 -2.5% - -
    4/1/2020 0.21 -14.8% - -
    4/1/2019 0.25 -14.5% - -
    4/1/2018 0.29 -9.5% - -
    4/1/2017 0.32 -18.1% - -
    4/1/2016 0.39 16.1% - -
    4/1/2015 0.34 346.7% - -
    4/1/2014 0.08 76.2% - -
    4/1/2013 0.04 -67.5% - -
    4/1/2012 0.13 106.9% - -
    4/1/2011 0.06 618.4% - -
    4/1/2010 0.01 -96.9% - -
    4/1/2009 0.28 -82.3% - -
    4/1/2008 1.6 -8.0% - -
    4/1/2007 1.74 -39.4% - -
    4/1/2006 2.87 80.0% - -
    4/1/2005 1.59 82.0% - -
    4/1/2004 0.88 -1.2% - -
    4/1/2003 0.89 51.5% - -
    4/1/2002 0.58 25.5% - -
    4/1/2001 0.47 -73.4% - -
    4/1/2000 1.75 202.5% - -
    4/1/1999 0.58 2923.9% - -
    4/1/1998 0.02 39.4% - -
    4/1/1997 0.01 87.9% - -
    4/1/1996 0.01 -93.1% - -
    4/1/1995 0.11 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
  • Long Term Debt/Equity Ratio = Long Term Debt / Shareholders Equity


    For more detailed definitions, please see Investopedia.
    Year Long Term Debt To Equity Ratio YoY % Change Stock Price YoY % Change (Stock Price) long term debt total se
    4/1/2021 0.21 -2.5% 9678.40 46604.80
    4/1/2020 0.21 -14.8% 9483.20 44585.30
    4/1/2019 0.25 -14.5% 9816.70 39402.60
    4/1/2018 0.29 -9.5% 10497.70 35942.90
    4/1/2017 0.32 -18.1% 11342.38 35179.10
    4/1/2016 0.39 16.1% 12886.82 32693.64
    4/1/2015 0.34 346.7% 11437.30 23624.66
    4/1/2014 0.08 76.2% 2195.45 11087.68
    4/1/2013 0.04 -67.5% 368.00 8627.21
    4/1/2012 0.13 106.9% 738.34 5969.90
    4/1/2011 0.06 618.4% 306.81 3770.33
    4/1/2010 0.01 -96.9% 26.27 3034.86
    4/1/2009 0.28 -82.3% 302.28 1335.40
    4/1/2008 1.60 -8.0% 781.00 510.15
    4/1/2007 1.74 -39.4% 722.00 422.55
    4/1/2006 2.87 80.0% 600.00 259.06
    4/1/2005 1.59 82.0% 600.00 397.97
    4/1/2004 0.88 -1.2% 480.00 564.35
    4/1/2003 0.89 51.5% 498.38 569.11
    4/1/2002 0.58 25.5% 495.68 856.75
    4/1/2001 0.47 -73.4% 495.68 1065.47
    4/1/2000 1.75 202.5% 471.35 276.46
    4/1/1999 0.58 2923.9% 150.61 130.10
    4/1/1998 0.02 39.4% 2.84 154.00
    4/1/1997 0.01 87.9% 1.66 88.30
    4/1/1996 0.01 -93.1% 0.53 71.47
    4/1/1995 0.11 1.60 15.20